• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AORT

    Artivion Inc.

    Subscribe to $AORT
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

    IPO Year:

    Exchange: NYSE

    Website: https://artivion.com

    Recent Analyst Ratings for Artivion Inc.

    DatePrice TargetRatingAnalyst
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    8/8/2022$32.00Buy
    Lake Street
    3/3/2022$30.00Buy
    Stifel
    2/18/2022$39.00 → $30.00Buy
    Needham
    See more ratings

    Artivion Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

      30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA, May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS.  Patients enrolled were at high risk for open surgical repair

      5/5/25 7:00:00 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results

      ATLANTA, April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 201-689-8261 a few minutes p

      4/21/25 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

      ATLANTA, March 4, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 18, 2025.   A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page.  An archived copy of the webcast will be available for 90 days on the same websit

      3/4/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basisAchieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basisNet loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal yearAdju

      2/24/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results

      ATLANTA, Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on Monday, February 24, 2025 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 201-689-8

      2/10/25 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting

      Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation.

      1/27/25 8:00:00 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

      ATLANTA, Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections. An HDE is a marketing application for a product that has been designated a Humanita

      12/9/24 8:00:00 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Third Quarter 2024 Financial Results

      Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basisNet loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug AdministrationEnrollment completed in NEXUS TRIOMPHE clinical

      11/7/24 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion to Participate in Upcoming Investor Conferences

      ATLANTA, Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at the Lotte New York Palace. The Company's presentation is scheduled to begin at 1:15p.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be availabl

      11/5/24 4:15:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    Artivion Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel Holloway Jean F exercised 19,092 shares at a strike of $21.55 and sold $425,510 worth of shares (18,020 units at $23.61), increasing direct ownership by 0.55% to 197,184 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/12/25 3:41:12 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Davis John E exercised 15,910 shares at a strike of $21.55 and sold $356,549 worth of shares (15,100 units at $23.61), increasing direct ownership by 0.39% to 208,778 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/12/25 3:32:23 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • President & CEO Mackin James P exercised 75,615 shares at a strike of $21.55, was granted 115,701 shares and sold $2,190,848 worth of shares (88,439 units at $24.77), increasing direct ownership by 13% to 865,283 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/10/25 5:18:53 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • VP, Chief Accounting Officer Horton Amy was granted 10,261 shares and sold $25,995 worth of shares (1,048 units at $24.80), increasing direct ownership by 7% to 146,651 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/10/25 5:11:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Executive VP, CFO Berry Lance A was granted 48,100 shares and sold $121,764 worth of shares (4,909 units at $24.80), increasing direct ownership by 39% to 153,431 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/10/25 5:08:36 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Davis John E sold $64,939 worth of shares (2,618 units at $24.80) and was granted 25,654 shares, increasing direct ownership by 12% to 207,968 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/10/25 5:06:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SVP, Clinical & MD Affair Stanton Marshall S. was granted 19,240 shares and sold $39,761 worth of shares (1,603 units at $24.80), increasing direct ownership by 18% to 115,880 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/10/25 5:03:12 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SVP, General Counsel Holloway Jean F was granted 25,493 shares and sold $52,685 worth of shares (2,124 units at $24.80), increasing direct ownership by 14% to 196,112 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/10/25 5:00:44 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SVP, General Counsel Holloway Jean F sold $11,935 worth of shares (472 units at $25.29), decreasing direct ownership by 0.27% to 172,743 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/6/25 8:53:09 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/5/25 4:01:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    Artivion Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 23, 2023 - FDA Roundup: May 23, 2023

      For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

      5/23/23 4:06:19 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    Artivion Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

      Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.

      12/6/23 4:15:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Sequana Medical announces results of Special General Meeting of Shareholders

      PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso

      6/26/23 12:00:00 PM ET
      $AORT
      $PHAR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Elizabeth Hoff Joins Artivion Board of Directors

      ATLANTA, Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022. "We are excited to welcome Elizabeth to our Board of Directors," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Elizabeth brings a wealth of knowledge in the medical device industry demonstrated by her tenure in the aortic space leading teams focused on the development and commercial launch of innovative healthca

      9/29/22 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    Artivion Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artivion Inc.

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      11/8/24 10:29:29 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Artivion Inc.

      SC 13G - ARTIVION, INC. (0000784199) (Subject)

      3/11/24 5:45:25 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/14/24 6:18:56 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/13/24 4:58:54 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/8/24 10:20:08 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/14/23 1:37:03 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/10/23 3:44:34 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/9/23 11:07:45 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Artivion Inc.

      SC 13G - ARTIVION, INC. (0000784199) (Subject)

      2/6/23 3:00:54 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Artivion Inc.

      SC 13D - ARTIVION, INC. (0000784199) (Subject)

      9/26/22 2:55:57 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    Artivion Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/5/25 4:01:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    Artivion Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Artivion with a new price target

      JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

      10/23/24 6:17:27 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street reiterated coverage on Artivion with a new price target

      Lake Street reiterated coverage of Artivion with a rating of Buy and set a new price target of $28.00 from $32.00 previously

      9/27/22 11:06:42 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Artivion with a new price target

      Lake Street initiated coverage of Artivion with a rating of Buy and set a new price target of $32.00

      8/8/22 9:08:33 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Artivion with a new price target

      Stifel initiated coverage of Artivion with a rating of Buy and set a new price target of $30.00

      3/3/22 4:38:35 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Needham reiterated coverage on Artivion with a new price target

      Needham reiterated coverage of Artivion with a rating of Buy and set a new price target of $30.00 from $39.00 previously

      2/18/22 5:52:23 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    Artivion Inc. Financials

    Live finance-specific insights

    See more
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basisAchieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basisNet loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal yearAdju

      2/24/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Third Quarter 2024 Financial Results

      Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basisNet loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug AdministrationEnrollment completed in NEXUS TRIOMPHE clinical

      11/7/24 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Second Quarter 2024 Financial Results

      Second Quarter Highlights:  Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency basisNet loss was ($2.1) million or ($0.05) per fully diluted share and non-GAAP net income was $2.9 million or $0.07 per fully diluted share in the second quarter of 2024Adjusted EBITDA increased 35% to $18.6 million in the second quarter of 2024 compared to $13.8 million in the second quarter of 2023Raised FY24 revenue guidance to 10% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpointRaised FY24 adjusted EBITDA guidance to 28% to 34% year-over-year g

      8/8/24 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports First Quarter 2024 Financial Results

      First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP constant currency basisNet income was $7.5 million or $0.18 per fully diluted share and non-GAAP net income was $2.6 million or $0.06 per fully diluted share in the first quarter of 2024Non-GAAP adjusted EBITDA increased 60% to $17.3 million in the first quarter of 2024 compared to $10.8 million in the first quarter of 2023Revised FY24 revenue guidance to 9% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpointATLANTA, May 6, 2024 /PRNewswire/ -- Artivion,

      5/6/24 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

      Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basisAchieved revenue of $354.0 million for the full year of 2023 versus $313.8 million for the full year of 2022, an increase of 13% on a GAAP basis and 12% on a non-GAAP constant currency basisNet loss was ($4.0) million or ($0.10) per fully diluted share and non-GAAP net income was $4.6 million or $0.11 per fully diluted share in the fourth quarter of 2023Non-GAAP adjusted EBITDA increased 40% to $15.3 million in the fourth quarter of 2023 compared to $11

      2/15/24 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Second Quarter 2023 Financial Results

      Second Quarter and Recent Business Highlights: Achieved revenue of $89.3 million in the second quarter of 2023 versus $80.3 million in the second quarter of 2022, an increase of 11% on both a GAAP and non-GAAP constant currency basisNet loss was ($3.4) million or ($0.08) per share; non-GAAP net income was $2.3 million or $0.06 per shareAchieved EBITDA of $9.2 million in the second quarter of 2023; non-GAAP adjusted EBITDA increased 35% to $13.8 million in the second quarter of 2023 compared to the second quarter of 2022Aortic stent graft revenues increased 19% on both a GAAP and non-GAAP constant currency basis in the second quarter of 2023 compared to the second quarter of 2022On-X revenues

      8/3/23 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports First Quarter 2023 Financial Results

      First Quarter and Recent Business Highlights: Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basisOn-X revenues increased 23% on a GAAP basis and 24% on a non-GAAP constant currency basis in the first quarter of 2023 compared to the first quarter of 2022Aortic stent graft revenues increased 3% on a GAAP basis and 8% on a non-GAAP constant currency basis in the first quarter of 2023 compared to the first quarter of 2022Received notice from the FDA that the PerClot PMA is approvable subject to finalization of the Establishment Inspection Re

      5/4/23 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Fourth Quarter and Full Year 2022 Financial Results

      Fourth Quarter and Recent Business Highlights: Achieved revenue of $79.4 million in the fourth quarter of 2022 versus $79.4 million in the fourth quarter of 2021, flat on a GAAP basis and an increase of 5% on a non-GAAP constant currency basisAchieved revenue of $313.8 million for the full year of 2022 versus $298.8 million for the full year of 2021, an increase of 5% on a GAAP basis and 9% on a non-GAAP constant currency basisOn-X revenues increased 8% on a GAAP basis and 11% on a non-GAAP constant currency basis in the fourth quarter of 2022 compared to the fourth quarter of 2021Aortic stent graft revenues increased 2% on a GAAP basis and 16% on a non-GAAP constant currency basis in the fo

      2/16/23 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Third Quarter 2022 Financial Results

      Third Quarter and Recent Business Highlights: Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11% on a non-GAAP constant currency basisOn-X revenues increased 17% on a GAAP basis and 19% on a non-GAAP constant currency basis in the third quarter of 2022 compared to the third quarter of 2021ATLANTA, Nov. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the third quarter ended September 30, 2022.

      11/3/22 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    Artivion Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Artivion Inc.

      10-Q - ARTIVION, INC. (0000784199) (Filer)

      5/6/25 3:10:43 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      5/5/25 4:08:44 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Artivion Inc.

      DEFA14A - ARTIVION, INC. (0000784199) (Filer)

      4/1/25 4:49:56 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Artivion Inc.

      DEF 14A - ARTIVION, INC. (0000784199) (Filer)

      4/1/25 4:46:44 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Artivion Inc.

      144 - ARTIVION, INC. (0000784199) (Subject)

      3/11/25 4:48:45 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Artivion Inc.

      10-K - ARTIVION, INC. (0000784199) (Filer)

      2/28/25 2:28:16 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      2/24/25 4:08:45 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      12/23/24 4:04:37 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      12/9/24 8:05:02 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      12/9/24 7:00:18 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care